A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination with Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft Versus Host Disease

Protocol No
INCYTE-INCB-39110-119-GRAVITAS
Principal Investigator
Nirav Shah
Phase
I
Summary
Find out more about the side effects of a new drug for GVHD, itacitinib and what doses of itacitinib are safe for people to take.
Description
Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis GVHD
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: